Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO

Sponsors

Lead Sponsor: GlaxoSmithKline

Source GlaxoSmithKline
Brief Summary

The study will evaluate the ability of GSK1278863 to increase the hemoglobin (Hgb) concentration, or maintain it within the target range, and the safety and efficacy of GSK1278863 over 16 weeks of treatment, in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are chronically hyporesponsive to rhEPO. The data generated will inform dose requirements for any chronic rhEPO hyporesponsive hemodialysis-dependent subjects included in future clinical trials. The study consists of a 4-week rhEPO run-in period, a 16-week GSK1278863 treatment period and a 4-week Follow-up period.

Overall Status Terminated
Start Date June 1, 2014
Completion Date March 16, 2016
Primary Completion Date March 1, 2016
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16 Week 16
Secondary Outcome
Measure Time Frame
Change From Baseline in Hgb Levels at Week 16 Week 16
Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time Point Week 12 to Week 16
Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16 Baseline and Week 16
Number of Participants With Hgb in the Target Range at Week 16 Week 16
Number of Participants Reaching Pre-defined Hgb Stopping Criteria Up to Week 16
Percent Change From Baseline in Hepcidin at Week 16 Baseline (Day 1) and Week 16
Change From Baseline in Ferritin at Week 16 Baseline (Day 1) and Week 16
Change From Baseline in Transferrin at Week 16 Baseline (Day 1) and Week 16
Percent Change From Baseline in Transferrin Saturation at Week 16 Baseline (Day 1) and Week 16
Change From Baseline in Total Iron at Week 16 Baseline (Day 1) and Week 16
Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 16 Baseline (Day 1) and Week 16
Reticulocyte Hgb Content (CHr) at Week 16 Week 16
Mean Corpuscular Volume (MCV) at Week 16 Week 16
Mean Corpuscular Hemoglobin (MCH) at Week 16 Week 16
Change From Baseline in Hematocrit at Week 16 Baseline (Day 1) and Week 16
Change From Baseline in Red Blood Cell (RBC) at Week 16 Baseline (Day 1) and Week 16
Change From Baseline in Reticulocyte Number at Week 16 Baseline (Day 1) and Week 16
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF) Baseline (Day 1) to Week 16
Maximum Observed Change From Baseline in Erythropoietin (EPO) Baseline (Day 1) to Week 16
Final Dose of GSK1278863 Up to 16 Weeks
Plasma Concentrations of GSK1278863 and Its Metabolites at the Indicated Time Points Day 1, Week 4 and Week 12
Enrollment 15
Condition
Intervention

Intervention Type: Drug

Intervention Name: GSK1278863

Description: Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863

Arm Group Label: GSK1278863 Arm

Intervention Type: Drug

Intervention Name: Placebo

Description: Matching placebo tablet for GSK1278863

Arm Group Label: GSK1278863 Arm

Eligibility

Criteria:

Inclusion Criteria:

- Hemodialysis (HD) frequency: Stable HD regimen of three to four times weekly for a minimum of 12 weeks. Note: The type and frequency of dialysis must be stable during the study. Isolated ultrafiltration sessions for the purposes of fluid removal are permitted.

- Dialysis Adequacy: Single-pool dialyzer clearance multiplied by dialyzer time divided by volume of distribution of urea (Kt/Vurea) of >=1.2 based on a historical value obtained within the prior month.

- rhEPO hyporesponsiveness: Historical and current intravenous (IV) rhEPO and Hgb values. Average epoetin alfa dose and Hgb level for three 4-week periods for a total of 12 weeks prior to Week -4, and during the 4 week run-in period, must be within the following ranges: average epoetin alfa dose >4000 and <=6000 units per session and Hgb >=8.0 and <=9.5 g/dL; average epoetin alfa dose >6000 and <=8000 units per session and Hgb >=8.0 and <=10.0 g/dL; average epoetin alfa dose >8000 and <=10000 units per session and Hgb >=8.0 and <=10.5 g/dL; and average epoetin alfa dose >10000 units per session and Hgb >=8.0 and <=11.0 g/dL.

- Absolute difference between the Hgb value at Week -4 and Week 0 (Day 1), must be <1.3 g/dL. Note: Subjects who do not meet the criteria after being rescreened twice, should not be entered into the GSK1278863 treatment period and should be withdrawn from the study.

- Age: >=18 years of age.

- Q-T Interval Corrected for Heart Rate (QTc): Bazett's Correction of QT Interval (QTcB) <470 msec or QTcB <480 milliseconds (msec) in subjects with bundle branch block. There is no corrected QT interval (QTc) inclusion criterion for a subject with a predominantly paced rhythm.

- Gender: Female and male subjects. Females: If of childbearing potential, must agree to use one of the approved contraception methods from Screening until completion of the Follow-up Visit OR, of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy or oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 23.0-116.3 milliinternational units (MIU)/milliliter (mL) (23.0-116.3 international units (IU)/liter (L)) and estradiol <=10 picograms (pg)/mL (<=37 picomole (pmol)/L) is confirmatory]. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.

Exclusion Criteria:

- Dialysis modality: Planned change in dialysis modality within the study time period.

- rhEPO: Use of methoxy polyethylene glycol epoetin beta or darbepoetin within the prior 8 weeks prior to Week -4.

- Renal transplant: Scheduled renal transplant.

- Transferrin saturation (TSAT): <20% on the most recent sample taken over the last 12 weeks.

- Ferritin: <100 nanograms (ng)/mL (<100 micrograms/L) on the most recent sample taken over the last 12 weeks.

- Vitamin B12: At or below the lower limit of the reference range (may rescreen in a minimum of 8 weeks).

- Folate: <2.0 ng/mL (<4.5 nanomoles (nmol)/L) (may rescreen in a minimum of 4 weeks).

- Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Week -4.

- Stroke or transient ischemic attacks (TIAs): Within the 8 weeks prior to Week -4.

- Heart failure: Class III/IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system diagnosed prior to Week -4.

- Hypertension: Defined using pre-dialysis vitals (Week -4) of diastolic blood pressure >100 millimeters of mercury (mmHg) or systolic blood pressure >170 mmHg.

- Thrombotic disease: History of thrombotic disease (e.g., venous thrombosis such as deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset or worsening limb ischemia requiring intervention) within the 8 weeks prior to Week -4, except vascular access thrombosis.

- Inflammatory disease: Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) diagnosed prior to Week -4.

- Hematological disease: Any hematological disease including those affecting platelets, white or red blood cells (e.g., antibody-mediated pure red cell aplasia, sickle cell anemia, myelodysplastic syndromes, hematological malignancy, myeloma, hemolytic anemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other cause of anemia other than renal disease diagnosed prior to Week -4.

- Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [alanine transaminase (ALT) or aspartate transaminase (AST) > 2.0 x upper limit of normal (ULN) or total bilirubin > 1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participation in the study. NOTE: Those with Hepatitis B or Hepatitis C are eligible provided these exclusions are not met.

- Major surgery: (excluding vascular access surgery) within the 8 weeks prior to Week -4, or planned during the study.

- Transfusion: Blood transfusion within the 8 weeks prior to Week -4, or an anticipated need for blood transfusion during the study.

- Gastrointestinal (GI) Bleeding: Evidence of actively bleeding peptic, duodenal, or esophageal ulcer disease or clinically significant GI bleeding within the 8 weeks prior to Week -4.

- Ophthalmology disease: History of proliferative retinopathy requiring treatment within the prior 12 months or macular edema requiring treatment.

- Acute infection: Clinical evidence of acute infection, evidence of underlying infection or history of infection requiring IV antibiotic therapy within the 8 weeks prior to Week -4, and also through to Day 1. Note: IV antibiotics as prophylaxis are allowed.

- Malignancy: Subjects with a history of malignancy within the prior 5 years, who are receiving treatment for cancer, or who have a strong family history of cancer (e.g., familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to Week -4.

- Severe allergic reactions: History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product.

- Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from Week -4 until the Follow-up Visit.

- Prior investigational product exposure: The subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days to Week -4.

- Life Expectancy: Life expectancy is considered by the investigator to be less than 6 months.

- Other conditions: Any other conditions, clinical or laboratory abnormality, or examination finding that the Investigator considers would put the subject at unacceptable risk, or an unwillingness or inability to follow the procedures, or lifestyle and/or dietary restrictions outlined in the protocol.

- Pregnancy and lactation: Pregnant females as determined by positive serum human chorionic gonadotrophin (hCG) test or women who are lactating at Week -4 or during the trial.

- Laboratory eligibility criteria will be assessed according to the central laboratory result for the screening samples

- Subjects who fail screening may be rescreened as soon as the investigator feels they may have subsequently become eligible. However, an individual subject may not be rescreened more than twice. There is no predetermined amount of time required to wait to rescreen a previously ineligible subject. Exceptions are those failing on Hgb or folate who may rescreen in 4 weeks and those failing for Vitamin B12 where rescreening may occur in 8 weeks.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
GSK Clinical Trials Study Director GlaxoSmithKline
Location
Facility:
GSK Investigational Site | Azusa, California, 91702, United States
GSK Investigational Site | Glendale, California, 91204, United States
GSK Investigational Site | Los Angeles, California, 90022, United States
GSK Investigational Site | Los Angeles, California, 90025, United States
GSK Investigational Site | Paramount, California, 90723, United States
GSK Investigational Site | San Diego, California, 92115, United States
GSK Investigational Site | Simi Valley, California, 93065, United States
GSK Investigational Site | Middlebury, Connecticut, 06762, United States
GSK Investigational Site | Hollywood, Florida, 33024, United States
GSK Investigational Site | Tampa, Florida, 33609, United States
GSK Investigational Site | Macon, Georgia, 31217, United States
GSK Investigational Site | Southgate, Michigan, 48195, United States
GSK Investigational Site | Saint Ann, Missouri, 63074, United States
GSK Investigational Site | Saint Louis, Missouri, 63110, United States
GSK Investigational Site | Amherst, New York, 14226, United States
GSK Investigational Site | Asheville, North Carolina, 28801, United States
GSK Investigational Site | Bethlehem, Pennsylvania, 18017, United States
GSK Investigational Site | Knoxville, Tennessee, 37923, United States
GSK Investigational Site | Houston, Texas, 77004, United States
Location Countries

United States

Verification Date

April 2017

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: GSK1278863 Arm

Type: Experimental

Description: Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov